Novartis’ Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.
Access articles & resources worth up to US $4, 000 per month.
This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.
First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved
Melinta Therapeutics Receives CARB-X Funding to Develop New Antibiotics Against Multiple “Superbugs”
First CAR-T GeneTherapy for Pediatric Blood Cancer ‘Kymriah’ Now Treats Adult Patients
First Drug to Treat Polycystic Kidney Disease Bags FDA Approval
7 New Ideas to Start a Healthcare Business in India (2018)
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply